Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ897MR)

This product GTTS-WQ897MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ897MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13921MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ9398MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Iomab-B
GTTS-WQ13579MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ6523MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ5275MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ11662MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ8806MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ10347MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY 3090106
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW